Document Detail


Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
MedLine Citation:
PMID:  18556716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: This study sought to investigate the 2-year outcomes of patients treated with the paclitaxel-eluting TAXUS((R)) stent (PES) or vascular brachytherapy (VBT), the previous 'gold standard therapy', for bare metal stent in-stent restenosis (ISR). METHODS AND RESULTS: In the TAXUS V-ISR trial, 396 patients with bare metal stent ISR referred for percutaneous coronary intervention were prospectively randomized to either PES or beta source VBT. The present analysis reports 24-month clinical outcomes from that study. Between 9 and 24 months, ischaemia-driven target lesion revascularization tended to be required less frequently with assignment to PES compared to VBT (5.3 vs. 10.3%, P = .07). As a result, ischaemia-driven target lesion revascularization at 24 months was significantly reduced with PES compared with VBT (10.1 vs. 21.6%, P = 0.003), as was ischaemia-driven target vessel revascularization (18.1 vs. 27.5%, P = .03). There were no significant differences between the two groups with regard to death, myocardial infarction, or target vessel thrombosis either between 12 and 24 months, or cumulative to 24 months. CONCLUSION: Freedom from clinical restenosis at 2 years is significantly enhanced after PES placement compared with VBT for bare metal stent ISR, with similar rates of death, myocardial infarction, and target vessel thrombosis.
Authors:
Stephen G Ellis; Charles D O'Shaughnessy; Steven L Martin; Kenneth Kent; Thomas McGarry; Mark A Turco; Dean J Kereiakes; Jeffrey J Popma; Mark Friedman; Joerg Koglin; Gregg W Stone;
Related Documents :
15166916 - Pre-existing anticardiolipin antibodies and development of restenosis after coronary ba...
12093056 - Routine intracoronary beta-irradiation. acute and one year outcome in patients at high ...
18208656 - Effects of sirolimus-eluting stent on calcified coronary lesions.
21558446 - Tvp1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume ove...
24492986 - Early 'in-lab' use of levosimendan in patients with cardiogenic shock unsuitable for in...
1864666 - Coronary angioplasty with second generation monorail catheters.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-06-13
Journal Detail:
Title:  European heart journal     Volume:  29     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-02     Completed Date:  2008-10-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  1625-34     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA. elliss@ccf.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Brachytherapy*
Coronary Restenosis / mortality,  therapy*
Drug-Eluting Stents*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Myocardial Infarction / etiology,  mortality
Paclitaxel / administration & dosage*
Risk Factors
Treatment Outcome
Tubulin Modulators / administration & dosage*
Chemical
Reg. No./Substance:
0/Tubulin Modulators; 33069-62-4/Paclitaxel
Comments/Corrections
Comment In:
Eur Heart J. 2008 Jul;29(13):1595-6   [PMID:  18556717 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Time course of functional recovery after revascularization of hibernating myocardium: a contrast-enh...
Next Document:  Impact of coronary revascularization and transmural extent of scar on regional left ventricular remo...